Show simple item record

dc.contributor.authorAfolabi, Bosede B.
dc.contributor.authorBabah, Ochuwa A.
dc.contributor.authorAkinajo, Opeyemi R.
dc.contributor.authorAdaramoye, Victoria O.
dc.contributor.authorAdeyemo, Titilope A.
dc.contributor.authorBalogun, Mobolanle
dc.contributor.authorBanke-Thomas, Aduragbemi
dc.contributor.authorQuao, Rachel A.
dc.contributor.authorOlorunfemi, Gbenga
dc.contributor.authorAbioye, Ajibola I.
dc.contributor.authorGaladanci, Hadiza S.
dc.contributor.authorSam-Agudu, Nadia A.
dc.date.accessioned2022-09-21T17:09:32Z
dc.date.available2022-09-21T17:09:32Z
dc.date.issued2022-09-08
dc.identifier.urihttp://hdl.handle.net/10713/19830
dc.description.abstractBACKGROUND: Anaemia in pregnancy is highly prevalent in African countries. High-dose oral iron is the current recommended treatment for pregnancy-related iron deficiency anaemia (IDA) in Nigeria and other African countries. This oral regimen is often poorly tolerated and has several side effects. Parenteral iron preparations are now available for the treatment of IDA in pregnancy but not widely used in Africa. The IVON trial is investigating the comparative effectiveness and safety of intravenous ferric carboxymaltose versus oral ferrous sulphate standard-of-care for pregnancy-related IDA in Nigeria. We will also measure the implementation outcomes of acceptability, feasibility, fidelity, and cost-effectiveness for intravenous ferric carboxymaltose. METHODS: This is an open-label randomised controlled trial with a hybrid type 1 effectiveness-implementation design, conducted at 10 health facilities in Kano (Northern) and Lagos (Southern) states in Nigeria. A total of 1056 pregnant women at 20-32 weeks' gestational age with moderate or severe anaemia (Hb < 10g/dl) will be randomised 1:1 into two groups. The interventional treatment is one 1000-mg dose of intravenous ferric carboxymaltose at enrolment; the control treatment is thrice daily oral ferrous sulphate (195 mg elemental iron daily), from enrolment till 6 weeks postpartum. Primary outcome measures are (1) the prevalence of maternal anaemia at 36 weeks and (2) infant preterm birth (<37 weeks' gestation) and will be analysed by intention-to-treat. Maternal full blood count and iron panel will be assayed at 4 weeks post-enrolment, 36 weeks' gestation, delivery, and 6 weeks postpartum. Implementation outcomes of acceptability, feasibility, fidelity, and cost will be assessed with structured questionnaires, key informant interviews, and focus group discussions. DISCUSSION: The IVON trial could provide both effectiveness and implementation evidence to guide policy for integration and uptake of intravenous iron for treating anaemia in pregnancy in Nigeria and similar resource-limited, high-burden settings. If found effective, further studies exploring different intravenous iron doses are planned.en_US
dc.description.sponsorshipBill and Melinda Gates Foundationen_US
dc.description.urihttps://doi.org/doi:10.1186/s13063-022-06690-2en_US
dc.relation.ispartofTrialsen_US
dc.subjectAnaemia in pregnancyen_US
dc.subjectAnaemia, iron deficiencyen_US
dc.subjectCost-effectivenessen_US
dc.subjectDepressionen_US
dc.subjectFerric carboxymaltoseen_US
dc.subjectFerrous sulphateen_US
dc.subjectImplementation scienceen_US
dc.subjectPregnancyen_US
dc.subjectProtocolen_US
dc.titleIntravenous versus oral iron for iron deficiency anaemia in pregnant Nigerian women (IVON): study protocol for a randomised hybrid effectiveness-implementation trialen_US
dc.typeArticleen_US
dc.identifier.doi10.1186/s13063-022-06690-2
dc.source.journaltitleTrials
dc.source.volume23
dc.source.issue1
dc.source.beginpage763
dc.source.endpage


This item appears in the following Collection(s)

Show simple item record